Increase in treatment of severe retinopathy of prematurity following a new national guideline

A (n=16 infants, 32 eyes) B (n= 41 infants, 79 eyes) p-value Neonatal Characteristics

GA* 25.2 (1.4) 26.2 (2.1) 0.204**

BW* 715 (184) 730 (205) 0.972**

Obstetric characteristics and interventions

Prenatal glucocorticoids 64.3% 75.7% 0.473† Multiple birth 25.0% 46.0% 0.116† Neonatal morbidity Sepsis 68.8% 74.4% 0.753† IVH/PVL 43.8% 24.4% 0.062† IRDS 93.7% 92.3% 1.000† BPD 68.6% 69.2% 0.259†

NEC with perforation 12.5% 21.8% 0.815†

Hyperglycaemia (> 8 mmol/l) 56.3% 30.8% 0.081† Neonatal Interventions Packed cells 93.8% 91.7% 0.795* iNO 18.8% 21.1% 0.819* Postnatal glucocorticoids 100% 58.8% 0.058*** AV > 7 days 87.5% 84.6% 0.783* Treatment characteristics

PMA at first ROP detection* 33.7 (1.64) 33.7 (3.71) 0.832**

PMA at treatment decision* 34.8 (1.29) 36.1 (3.71) 0.025**

PMA at treatment* 34.9 (1.93) 36.8 (3.93) 0.070**

Table 1. Risk factors and treatment characteristics in the groups treated according to the old (A) vs. new (B)

Dutch retinopathy of prematurity-guideline.

AV, artificial ventilation; BPD, bronchopulmonary dysplasia; BW, birth weight; GA, gestational age; iNO, inhaled

nitric oxide, IRDS, infant respiratory distress syndrome; IQR, inter quartile range; IVH, intraventricular

haemorrhage; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PMA, post menstrual age;

PVL, periventricular leukomalacia.